People · Operator
Named in public records as an officer, director or promoter · active 2020–2026 · Other, Other Health Care, Pharmaceuticals, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Grove, Inc. | — | Other | Series D+ | $309.0M | $1.6B | 2021 |
| DermTech, Inc. | — | Other Health Care | Series C | $98.9M | $1.5B | 2020 |
| Cure Pharmaceutical Holding Corp. | — | Pharmaceuticals | Series B | $31.5M | $342.9M | 2020 |
| Upexi, Inc. | Director | Other | Series B | $19.5M | $73.9M | 2026 |
| Adaptiiv Medical Technologies Inc. | — | Healthtech | Seed | $3.6M | $3.5M | 2025 |
Gene Salkind at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gene Salkind on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Norstrud | 2 | 4 |
| Thomas Williams | 2 | 3 |
| ALLAN MARSHALL | 2 | 2 |
| Gary Jacobs | 1 | 11 |
| Bruce Ross | 1 | 7 |
| Enrico Picozza | 1 | 7 |
| John Bell | 1 | 5 |
| ALI RIAZ | 1 | 5 |
| Alex Katz | 1 | 5 |
| Matthew Posard | 1 | 4 |
| Michael Willis | 1 | 4 |
| Thomas C. Williams | 1 | 4 |
| PETER HICKEY | 1 | 3 |
| CHARLES BERMAN | 1 | 3 |
| Robert Davidson | 1 | 3 |
| Robert Hackett | 1 | 2 |
| ALEX DUNPHY | 1 | 2 |
| Burkhard Jansen | 1 | 2 |
| Mark Udell | 1 | 2 |
| Edward Maliski | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.